The American healthcare company, CVS Health, has decided to remove the cold and cough pills containing phenylephrine from the drug stores.
The following decision comes after the health regulator, the US Food and Drug Administration (FDA) determines the decongestant is ineffective towards flu if
taken orally.
However, when ingested in pill or tablet form, this ingredient fails to reach its destination from the stomach to the nasal passages.
CVS Health spokesperson told USA Today, "We are removing a small number of oral decongestant products that contain phenylephrine as the only active ingredient
from CVS Pharmacy stores but will continue offering many other oral cough and cold products to meet consumer needs."
They almost run more than 9,000 stores in the US whereas their rival, Walgreens has not yet taken the step to remove over-the-counter medications from their shelves.
The Scottish Medicines Consortium (SMC) has accepted AbbVie's RINVOQ (upadacitinib) for use within NHS Scotland for the treatment of adult patients with
moderately to severely active ulcerative colitis (UC).
Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors.
"Daily life with ulcerative colitis is difficult due to the debilitating and unpredictable nature of its symptoms", said Dr Jonathan Macdonald, Consultant
Gastroenterologist at NHS Greater Glasgow and Clyde.
"Clinical trials have shown that upadacitinib as a once daily pill controls symptoms in eight weeks for many patients and provided sustained responses at one year.
The SMC's decision is good news for people with ulcerative colitis in Scotland as it provides an additional treatment option to help them gain control of their
condition."
The SMC decision is based on data from the induction studies U-ACHIEVE and U-ACCOMPLISH, as well as the Phase 3 U-ACHIEVE maintenance study, which demonstrated the
efficacy of upadacitinib versus placebo in its ability to achieve clinical remission. The SMC's decision follows the granting of Marketing Authorisation for
upadacitinib in UC in July 2022.